These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22889814)

  • 1. Factor V Leiden: to test or not to test, that is the debate.
    Makris M
    Blood Transfus; 2012 Jul; 10(3):255-6. PubMed ID: 22889814
    [No Abstract]   [Full Text] [Related]  

  • 2. Utility of testing for factor V Leiden.
    Franchini M
    Blood Transfus; 2012 Jul; 10(3):257-9. PubMed ID: 22889815
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation factor V and thrombophilia: background and mechanisms.
    Segers K; Dahlbäck B; Nicolaes GA
    Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm.
    Van Cott EM; Soderberg BL; Laposata M
    Arch Pathol Lab Med; 2002 May; 126(5):577-82. PubMed ID: 11958664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Futility of testing for factor V Leiden.
    Favaloro EJ; McDonald D
    Blood Transfus; 2012 Jul; 10(3):260-3. PubMed ID: 22889816
    [No Abstract]   [Full Text] [Related]  

  • 7. Activated protein C resistance, factor V Leiden, and retinal vessel occlusion.
    Ma AD; Abrams CS
    Retina; 1998; 18(4):297-300. PubMed ID: 9730170
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombo-embolic disease--prevalence of factor V Leiden in the Western Cape.
    Rubinstein R; Novitzky N
    S Afr Med J; 2001 May; 91(5):406. PubMed ID: 11455804
    [No Abstract]   [Full Text] [Related]  

  • 9. Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states.
    Nicolaes GA; Dahlbäck B
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):37-61, vi. PubMed ID: 12627662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of activated protein C resistance phenotype in subjects with compound heterozygosity for HR2 haplotype and FV Leiden mutation (R506Q) in factor V gene.
    Castaman G; Ruggeri M; Tosetto A; Rodeghiero F
    Thromb Haemost; 2000 Aug; 84(2):357-8. PubMed ID: 10959717
    [No Abstract]   [Full Text] [Related]  

  • 11. Factor V mutations in Iranian patients with activated protein C resistance and venous thrombosis.
    Chegeni R; Kazemi B; Hajifathali A; Pourfathollah A; Lari GR
    Thromb Res; 2007; 119(2):189-93. PubMed ID: 16542711
    [No Abstract]   [Full Text] [Related]  

  • 12. The discovery of activated protein C resistance.
    Dahlbäck B
    J Thromb Haemost; 2003 Jan; 1(1):3-9. PubMed ID: 12871530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
    Arnutti P; Hiyoshi M; Prayoonwiwat W; Nathalang O; Suwanasophon C; Kokaseam R; Tatsumi N
    Thromb Haemost; 1998 Aug; 80(2):344-5. PubMed ID: 9716166
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence of the Factor V Leiden Mutation Arg534Gln in Western Region of Saudi Arabia: Functional Alteration and Association Study With Different Populations.
    Athar M; Abduljaleel Z; Ghita IS; Albagenny AA; Halawani SH; Alkazmi MM; Elbjeirami WM; Alquthami K; Alkhuzae MM; Ragab FM; Al-Allaf FA
    Clin Appl Thromb Hemost; 2021; 27():1076029620978532. PubMed ID: 33448877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular implications of the factor V Leiden mutation.
    Major DA; Sane DC; Herrington DM
    Am Heart J; 2000 Aug; 140(2):189-95. PubMed ID: 10925328
    [No Abstract]   [Full Text] [Related]  

  • 16. Usefulness of factor V Leiden mutation testing in clinical practice.
    Blinkenberg EØ; Kristoffersen AH; Sandberg S; Steen VM; Houge G
    Eur J Hum Genet; 2010 Aug; 18(8):862-6. PubMed ID: 20332812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
    Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
    Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
    Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
    Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
    Kim TW; Kim WK; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Lee JS; Seo EJ; Chi HS; Kim SH
    J Korean Med Sci; 1998 Dec; 13(6):587-90. PubMed ID: 9886165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.